Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010
Jun 18, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference... More |
Jun 12, 2019 Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 2019 Life Sciences and MedTech Conference, at 11:30 a.m. ET,... More |
Jun 5, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance... More |
May 29, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths,... More |
May 24, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that the company's chief financial officer (CFO), Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the... More |
May 23, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 1, 2019. Following the appointment of Dr. Rewolinski, the... More |
May 21, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $30.5 million, face value, of its Term A Loans in a private transaction. "We are particularly... More |
May 16, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing a generic version of Adderall®, an immediate-release (IR) mixed salt of a single entity Amphetamine tablet product... More |
- Net Sales, Excluding Levothyroxine, Continues Sequential Quarterly Growth Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 third quarter ended March 31, 2019. "Our solid third quarter financial results reflect continued growth of... More |
Apr 30, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it expects to launch later this quarter Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54... More |